{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:33:38Z","timestamp":1768444418047,"version":"3.49.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to evaluate the implementation of the population- and family history (FH) -based screening for BReast CAncer (BRCA) in Iran, a country where less than 10% of breast cancer cases are attributable to a gene mutation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was an economic evaluation study. The Benefit-Cost Ratio (BCR) for genetic screening test strategies in Iranian women older than 30 was calculated. To this end, the monetary value of the test was estimated using the willingness-to-pay (WTP) approach using the contingent valuation method (CVM) by payment card. From a healthcare perspective, direct medical and non-medical costs were considered and a decision model for the strategies was developed to simulate the costs. A one-way sensitivity analysis assessed the robustness of the analysis. The data were analyzed using Excel 2010.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>660 women were included for estimating WTP and 2,176,919 women were considered in the costing model. The cost per genetic screening test for population- and FH-based strategies was $167 and $8, respectively. The monetary value of a genetic screening test was $20 and it was $27 for women with a family history or gene mutation in breast cancer. The BCR for population-based and FH-based screening strategies was 0.12 and 3.37, respectively. Sensitivity analyses confirmed the robustness of the results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study recommends the implementation of a FH-based strategy instead of a population-based genetic screening strategy in Iran, although a cascade genetic screening test strategy should be evaluated in future studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-12003-4","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T09:02:23Z","timestamp":1709283743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A cost-benefit analysis of genetic screening test for breast cancer in Iran"],"prefix":"10.1186","volume":"24","author":[{"given":"Zahra","family":"Meshkani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najmeh","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Aboutorabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Farabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazi","family":"Moini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"12003_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"12003_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149:778\u201389.","journal-title":"Int J Cancer"},{"key":"12003_CR3","doi-asserted-by":"publisher","first-page":"5748","DOI":"10.18632\/aging.202502","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang J, Chan PS, Lok V, et al. Global incidence and mortality of breast cancer: a trend analysis. Aging. 2021;13:5748.","journal-title":"Aging"},{"key":"12003_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","volume":"9","author":"S Chen","year":"2023","unstructured":"Chen S, Cao Z, Prettner K, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9:465\u201372.","journal-title":"JAMA Oncol"},{"key":"12003_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-017-4249-x","volume":"164","author":"BT Allaire","year":"2017","unstructured":"Allaire BT, Ekwueme DU, Poehler D, et al. Breast cancer treatment costs in younger, privately insured women. Breast Cancer Res Treat. 2017;164:429\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"12003_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-017-2006-9","volume":"17","author":"S Capri","year":"2017","unstructured":"Capri S, Russo A. Cost of breast cancer based on real-world data: a cancer registry study in Italy. BMC Health Serv Res. 2017;17:1\u201310.","journal-title":"BMC Health Serv Res"},{"key":"12003_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ajco.12703","volume":"14","author":"XZ Liao","year":"2018","unstructured":"Liao XZ, Shi JF, Liu JS, et al. Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross\u2010sectional study. Asia\u2010Pacific J Clin Oncol. 2018;14:167\u201378.","journal-title":"Asia\u2010Pacific J Clin Oncol"},{"key":"12003_CR8","doi-asserted-by":"publisher","first-page":"100447","DOI":"10.1016\/j.jcpo.2023.100447","volume":"38","author":"I Umo","year":"2023","unstructured":"Umo I, Kulai M, Umo P, et al. The direct medical cost of breast cancer management in a provincial hospital of Papua New Guinea: a cost of illness study of consecutive patients from 2017 to 2022. J Cancer Policy. 2023;38:100447.","journal-title":"J Cancer Policy"},{"key":"12003_CR9","doi-asserted-by":"crossref","unstructured":"Ramathebane M, Maja L, Sooro M et al. Assessing challenges and opportunities of treating breast cancer in Lesotho. Med Res Archives. 2023; 11.","DOI":"10.18103\/mra.v11i10.4583"},{"key":"12003_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-006-9270-4","volume":"101","author":"H Yasunaga","year":"2007","unstructured":"Yasunaga H, Ide H, Imamura T, et al. Women\u2019s anxieties caused by false positives in mammography screening: a contingent valuation survey. Breast Cancer Res Treat. 2007;101:59\u201364.","journal-title":"Breast Cancer Res Treat"},{"key":"12003_CR11","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/cancers15041124","volume":"15","author":"LS Velentzis","year":"2023","unstructured":"Velentzis LS, Freeman V, Campbell D, et al. Breast cancer risk assessment tools for stratifying women into risk groups: a systematic review. Cancers. 2023;15:1124.","journal-title":"Cancers"},{"key":"12003_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7314\/APJCP.2016.17.S3.149","volume":"17","author":"VR Yassaee","year":"2016","unstructured":"Yassaee VR, Ravesh Z, Soltani Z, et al. Mutation spectra of BRCA genes in Iranian women with early onset breast Cancer-15 years experience. Asian Pac J Cancer Prev. 2016;17:149\u201353.","journal-title":"Asian Pac J Cancer Prev"},{"key":"12003_CR13","unstructured":"WHO. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. 2024."},{"key":"12003_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jval.2019.03.008","volume":"22","author":"L Petelin","year":"2019","unstructured":"Petelin L, Hossack L, Mitchell G, et al. A microsimulation model for evaluating the effectiveness of cancer risk management for BRCA pathogenic variant carriers: miBRovaCAre. Value Health. 2019;22:854\u201362.","journal-title":"Value Health"},{"key":"12003_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10689-012-9530-x","volume":"11","author":"NJ Engel","year":"2012","unstructured":"Engel NJ, Gordon P, Thull DL, et al. A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Fam Cancer. 2012;11:419\u201327.","journal-title":"Fam Cancer"},{"key":"12003_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"BCA Consortium","year":"2021","unstructured":"Consortium BCA. Breast cancer risk genes\u2014association analysis in more than 113,000 women. N Engl J Med. 2021;384:428\u201339.","journal-title":"N Engl J Med"},{"key":"12003_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jama.2014.12483","volume":"312","author":"M-C King","year":"2014","unstructured":"King M-C, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA. 2014;312:1091\u201392.","journal-title":"JAMA"},{"key":"12003_CR18","first-page":"159","volume":"12","author":"K Zendehdel","year":"2020","unstructured":"Zendehdel K. Cancer statistics in IR Iran in 2020. Basic Clin Cancer Res. 2020;12:159\u201365.","journal-title":"Basic Clin Cancer Res"},{"key":"12003_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2298\/AOO190626007S","volume":"26","author":"S Sayad","year":"2020","unstructured":"Sayad S, Ahmadi SAY, Nekouian R, et al. Epidemiological and pathological characteristics of post-surgical cases of invasive breast cancer among ethnicities of Iran in 2018: a single center cross-sectional study. Archive Oncol. 2020;26:6\u20139.","journal-title":"Archive Oncol"},{"key":"12003_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12962-023-00470-8","volume":"21","author":"FS Jalali","year":"2023","unstructured":"Jalali FS, Keshavarz K, Seif M, et al. Economic burden of breast cancer: a case of Southern Iran. Cost Eff Resource Allocation. 2023;21:58.","journal-title":"Cost Eff Resource Allocation"},{"key":"12003_CR21","first-page":"579","volume":"46","author":"AA Valipour","year":"2017","unstructured":"Valipour AA, Mohammadian M, Ghafari M, et al. Predict the future incidence and mortality of breast cancer in Iran from 2012\u20132035. Iran J Public Health. 2017;46:579\u201380.","journal-title":"Iran J Public Health"},{"key":"12003_CR22","first-page":"74","volume":"17","author":"DM Noori","year":"2010","unstructured":"Noori DM, Tabarestani S. Molecular genetics, diagnosis and treatment of breast cancer. J Sabzevar Univ Med Sci. 2010;17:74\u201387.","journal-title":"J Sabzevar Univ Med Sci"},{"key":"12003_CR23","first-page":"71","volume":"3","author":"H Khaleghi Mahani","year":"2017","unstructured":"Khaleghi Mahani H, Ahmadi Tabatabaei SV, Mirzai M, et al. Breast self\u2013examination predictors based on Precede Model: a study on female active health volunteers in Zarand City. J Health Based Res. 2017;3:71\u201385.","journal-title":"J Health Based Res"},{"key":"12003_CR24","doi-asserted-by":"crossref","unstructured":"Dolatkhah R, Somi MH, Jafarabadi MA et al. Breast Cancer Survival and Incidence: 10 Years Cancer Registry Data in the Northwest, Iran. International journal of breast cancer. 2020; 2020.","DOI":"10.1155\/2020\/1963814"},{"key":"12003_CR25","unstructured":"http:\/\/grc.sbmu.ac.ir\/. 2020."},{"key":"12003_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/phgs.4.3.231.22691","volume":"4","author":"KA Phillips","year":"2003","unstructured":"Phillips KA, Veenstra D, Bebber SV, et al. An introduction to cost-effectiveness and cost\u2013benefit analysis of pharmacogenomics. Pharmacogenomics. 2003;4:231\u201339.","journal-title":"Pharmacogenomics"},{"key":"12003_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2165\/00019053-199915010-00002","volume":"15","author":"MV Bala","year":"1999","unstructured":"Bala MV, Mauskopf JA, Wood LL. Willingness to pay as a measure of health benefits. PharmacoEconomics. 1999;15:9\u201318.","journal-title":"PharmacoEconomics"},{"key":"12003_CR28","doi-asserted-by":"publisher","first-page":"e0231584","DOI":"10.1371\/journal.pone.0231584","volume":"15","author":"A Darvishi","year":"2020","unstructured":"Darvishi A, Goudarzi R, Zadeh VH, et al. Cost-benefit analysis of IUI and IVF based on willingness to pay approach; case study: Iran. PLoS ONE. 2020;15:e0231584.","journal-title":"PLoS ONE"},{"key":"12003_CR29","first-page":"A31","volume":"29","author":"L Sun","year":"2019","unstructured":"Sun L, Brentnall A, Patel S, et al. Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis. Int J Gynecol Cancer. 2019;29:A31.","journal-title":"Int J Gynecol Cancer"},{"key":"12003_CR30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","volume":"110","author":"R Manchanda","year":"2018","unstructured":"Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in unselected general population women. JNCI: J Natl Cancer Inst. 2018;110:714\u201325.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"12003_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ajog.2017.12.221","volume":"218","author":"S Patel","year":"2018","unstructured":"Patel S, Legood R, Evans DG, et al. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi jewish women. Am J Obstet Gynecol. 2018;218:431. e1-31. e12.","journal-title":"Am J Obstet Gynecol"},{"key":"12003_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ajog.2017.06.038","volume":"217","author":"R Manchanda","year":"2017","unstructured":"Manchanda R, Patel S, Antoniou AC, et al. Cost-effectiveness of population based BRCA testing with varying Ashkenazi jewish ancestry. Am J Obstet Gynecol. 2017;217:578. e1-78. e12.","journal-title":"Am J Obstet Gynecol"},{"key":"12003_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12687-016-0266-4","volume":"7","author":"I Slade","year":"2016","unstructured":"Slade I, Hanson H, George A, et al. A cost analysis of a cancer genetic service model in the UK. J Community Genet. 2016;7:185\u201394.","journal-title":"J Community Genet"},{"key":"12003_CR34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s12889-023-15568-0","volume":"23","author":"Z Meshkani","year":"2023","unstructured":"Meshkani Z, Moradi N, Aboutorabi A, et al. Subjective valuation of Iranian women for screening for gene-related diseases: a case of breast cancer. BMC Public Health. 2023;23:667.","journal-title":"BMC Public Health"},{"key":"12003_CR35","unstructured":"https:\/\/www.amar.org.ir\/. 2024."},{"key":"12003_CR36","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","volume":"66","author":"KE Malone","year":"2006","unstructured":"Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66:8297\u2013308.","journal-title":"Cancer Res"},{"key":"12003_CR37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jmedgenet-2017-104947","volume":"55","author":"WX Wen","year":"2018","unstructured":"Wen WX, Allen J, Lai KN, et al. Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. J Med Genet. 2018;55:97\u2013103.","journal-title":"J Med Genet"},{"key":"12003_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","volume":"52","author":"S Jervis","year":"2015","unstructured":"Jervis S, Song H, Lee A, et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet. 2015;52:465\u201375.","journal-title":"J Med Genet"},{"key":"12003_CR39","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/cancers12071929","volume":"12","author":"R Manchanda","year":"2020","unstructured":"Manchanda R, Sun L, Patel S, et al. Economic evaluation of Population-based BRCA1\/BRCA2 mutation testing across multiple countries and Health systems. Cancers. 2020;12:1929.","journal-title":"Cancers"},{"key":"12003_CR40","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10549-007-9571-2","volume":"107","author":"I Konstantopoulou","year":"2008","unstructured":"Konstantopoulou I, Rampias T, Ladopoulou A, et al. Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast\/ovarian cancer patients. Breast Cancer Res Treat. 2008;107:431\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"12003_CR41","doi-asserted-by":"publisher","first-page":"e0187630","DOI":"10.1371\/journal.pone.0187630","volume":"12","author":"B Alemar","year":"2017","unstructured":"Alemar B, Gregorio C, Herzog J, et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: are international testing criteria appropriate for this specific population? PLoS ONE. 2017;12:e0187630.","journal-title":"PLoS ONE"},{"key":"12003_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2107-6","volume":"16","author":"W-M Cao","year":"2016","unstructured":"Cao W-M, Gao Y, Yang H-J, et al. Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast\/ovarian cancer. BMC Cancer. 2016;16:1\u20139.","journal-title":"BMC Cancer"},{"key":"12003_CR43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103672","volume":"53","author":"K Kast","year":"2016","unstructured":"Kast K, Rhiem K, Wappenschmidt B, et al. Prevalence of BRCA1\/2 germline mutations in 21 401 families with breast and ovarian cancer. J Med Genet. 2016;53:465\u201371.","journal-title":"J Med Genet"},{"key":"12003_CR44","doi-asserted-by":"publisher","first-page":"80465","DOI":"10.18632\/oncotarget.12610","volume":"7","author":"GC Fernandes","year":"2016","unstructured":"Fernandes GC, Michelli RA, Galv\u00e3o HC, et al. Prevalence of BRCA1\/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016;7:80465.","journal-title":"Oncotarget"},{"key":"12003_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-13-243","volume":"13","author":"P Blay","year":"2013","unstructured":"Blay P, Santamar\u00eda I, Pitiot AS, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13:1\u201310.","journal-title":"BMC Cancer"},{"key":"12003_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ijc.27326","volume":"131","author":"JD Fackenthal","year":"2012","unstructured":"Fackenthal JD, Zhang J, Zhang B, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012;131:1114\u201323.","journal-title":"Int J Cancer"},{"key":"12003_CR47","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/cge.12505","volume":"88","author":"J Abugattas","year":"2015","unstructured":"Abugattas J, Llacuachaqui M, Allende YS, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet. 2015;88:371\u201375.","journal-title":"Clin Genet"},{"key":"12003_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02683-4","volume":"19","author":"DB Ayed-Guerfali","year":"2021","unstructured":"Ayed-Guerfali DB, Kridis-Rejab WB, Ammous-Boukhris N, et al. Novel and recurrent BRCA1\/BRCA2 germline mutations in patients with breast\/ovarian cancer: a series from the south of Tunisia. J Translational Med. 2021;19:1\u201310.","journal-title":"J Translational Med"},{"key":"12003_CR49","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ijc.32184","volume":"145","author":"M Deng","year":"2019","unstructured":"Deng M, Chen HH, Zhu X, et al. Prevalence and clinical outcomes of germline mutations in BRCA1\/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer. 2019;145:1517\u201328.","journal-title":"Int J Cancer"},{"key":"12003_CR50","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","volume":"77","author":"AB Skytte","year":"2010","unstructured":"Skytte AB, Gerdes AM, Andersen M, et al. Risk-reducing mastectomy and salpingo\u2010oophorectomy in unaffected BRCA mutation carriers: Uptake and timing. Clin Genet. 2010;77:342\u201349.","journal-title":"Clin Genet"},{"key":"12003_CR51","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1158\/1055-9965.EPI-09-0171","volume":"18","author":"DGR Evans","year":"2009","unstructured":"Evans DGR, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev. 2009;18:2318\u201324.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"12003_CR52","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.maturitas.2013.10.017","volume":"77","author":"CM van Driel","year":"2014","unstructured":"van Driel CM, Eltahir Y, de Vries J, et al. Risk-reducing mastectomy in BRCA1\/2 mutation carriers: factors influencing uptake and timing. Maturitas. 2014;77:180\u201384.","journal-title":"Maturitas"},{"key":"12003_CR53","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1016\/j.ejso.2021.03.248","volume":"47","author":"T Lo\u017ear","year":"2021","unstructured":"Lo\u017ear T, \u017dgajnar J, Perhavec A, et al. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia. Eur J Surg Oncol. 2021;47:1900\u201306.","journal-title":"Eur J Surg Oncol"},{"key":"12003_CR54","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer. 2008;122:2017\u201322.","journal-title":"Int J Cancer"},{"key":"12003_CR55","doi-asserted-by":"publisher","first-page":"680","DOI":"10.5694\/mja13.10848","volume":"199","author":"IM Collins","year":"2013","unstructured":"Collins IM, Milne RL, Weideman PC, et al. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers. Med J Aust. 2013;199:680\u201383.","journal-title":"Med J Aust"},{"key":"12003_CR56","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/tbj.12978","volume":"24","author":"J Long","year":"2018","unstructured":"Long J, Evans TG, Bailey D, et al. Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK. Breast J. 2018;24:580\u201385.","journal-title":"Breast J"},{"key":"12003_CR57","doi-asserted-by":"crossref","unstructured":"Tuffaha H, Scuffham P. Cost-effectivness analysis of germline BRCA mutation testing and olaparib treatment in metastatic breast cancer: an evaluation of codependent technologies value in Health. 2019; 22: S454.","DOI":"10.1016\/j.jval.2019.09.292"},{"key":"12003_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ygyno.2013.12.014","volume":"132","author":"C Garcia","year":"2014","unstructured":"Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132:428\u201333.","journal-title":"Gynecol Oncol"},{"key":"12003_CR59","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa020119","volume":"346","author":"ND Kauff","year":"2002","unstructured":"Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609\u201315.","journal-title":"N Engl J Med"},{"key":"12003_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00432-015-2051-x","volume":"142","author":"SI Kim","year":"2016","unstructured":"Kim SI, Lim MC, Lee DO, et al. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea. J Cancer Res Clin Oncol. 2016;142:333\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"key":"12003_CR61","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1023\/A:1015269620265","volume":"73","author":"LN Lodder","year":"2002","unstructured":"Lodder LN, Frets PG, Trijsburg RW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat. 2002;73:97\u2013112.","journal-title":"Breast Cancer Res Treat"},{"key":"12003_CR62","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/jnci\/djx265","volume":"110","author":"R Manchanda","year":"2018","unstructured":"Manchanda R, Patel S, Gordeev VS, et al. Cost-effectiveness of Population-based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 mutation testing in Unselected General Population women. J Natl Cancer Inst. 2018;110:714\u201325.","journal-title":"J Natl Cancer Inst"},{"key":"12003_CR63","first-page":"1","volume":"1","author":"ES Hashemi","year":"2008","unstructured":"Hashemi ES, Montazeri A, Kaviyani A, et al. The effect of duration of site drainage on serum incidence in breast cancer surgery (in persian). Iran Breast Dis Q. 2008;1:1\u20135.","journal-title":"Iran Breast Dis Q"},{"key":"12003_CR64","first-page":"368","volume":"67","author":"A Jangjo","year":"2009","unstructured":"Jangjo A, Mehrabi M, Akbarian MA. Seroma formation in breast cancer surgery: incidence and influencing factors in a prospective study (in persian). J School Med. 2009;67:368\u201373.","journal-title":"J School Med"},{"key":"12003_CR65","first-page":"78","volume":"15","author":"AMM AM","year":"2007","unstructured":"AM AMM. Breast Reconstruction after Mastectomy: luxury or necessity? Iran J Surg. 2007;15:78\u201383.","journal-title":"Iran J Surg"},{"key":"12003_CR66","first-page":"224","volume":"29","author":"FH Shandiz","year":"2015","unstructured":"Shandiz FH, Najafi MN, Shaye ZA, et al. Tendency to breast reconstruction after breast mastectomy among Iranian women with breast cancer. Med J Islamic Repub Iran. 2015;29:224.","journal-title":"Med J Islamic Repub Iran"},{"key":"12003_CR67","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/AOG.0b013e3182864350","volume":"121","author":"WH Parker","year":"2013","unstructured":"Parker WH, Feskanich D, Broder MS, et al. Long-term mortality associated with oophorectomy versus ovarian conservation in the nurses\u2019 health study. Obstet Gynecol. 2013;121:709.","journal-title":"Obstet Gynecol"},{"key":"12003_CR68","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","volume":"121","author":"A Finch","year":"2011","unstructured":"Finch A, Metcalfe K, Chiang J, et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol. 2011;121:163\u201368.","journal-title":"Gynecol Oncol"},{"key":"12003_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejca.2017.07.018","volume":"84","author":"RF Vermeulen","year":"2017","unstructured":"Vermeulen RF, van Beurden M, Kieffer JM, et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: a prospective study. Eur J Cancer. 2017;84:159\u201367.","journal-title":"Eur J Cancer"},{"key":"12003_CR70","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/pon.2041","volume":"22","author":"A Finch","year":"2013","unstructured":"Finch A, Metcalfe KA, Chiang J, et al. The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psycho\u2010oncology. 2013;22:212\u201319.","journal-title":"Psycho\u2010oncology"},{"key":"12003_CR71","doi-asserted-by":"publisher","first-page":"e0207993","DOI":"10.1371\/journal.pone.0207993","volume":"13","author":"L Sun","year":"2018","unstructured":"Sun L, Legood R, dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: a systematic review. PLoS ONE. 2018;13:e0207993.","journal-title":"PLoS ONE"},{"key":"12003_CR72","doi-asserted-by":"crossref","unstructured":"Guo F, Hirth JM, Fuchs EL et al. Knowledge, attitudes, willingness to pay, and patient preferences about genetic testing and subsequent risk management for cancer prevention. J Cancer Educ. 2020: 1\u20138.","DOI":"10.1007\/s13187-020-01823-0"},{"key":"12003_CR73","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.ejca.2014.03.272","volume":"50","author":"BM Behbahani","year":"2014","unstructured":"Behbahani BM, Tehrani TD, Gharibi F. P0228 knowledge, attitude, and practice of Iranian women towards breast cancer screening methods. Eur J Cancer. 2014;50:e73.","journal-title":"Eur J Cancer"},{"key":"12003_CR74","doi-asserted-by":"publisher","first-page":"dju380","DOI":"10.1093\/jnci\/dju380","volume":"107","author":"R Manchanda","year":"2015","unstructured":"Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history\u2013based testing. J Natl Cancer Inst. 2015;107:dju380.","journal-title":"J Natl Cancer Inst"},{"key":"12003_CR75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.15171\/ijhpm.2014.44","volume":"2","author":"N Hatam","year":"2014","unstructured":"Hatam N, Keshtkar V, Salehi A, et al. The financial cost of preventive and curative programs for breast cancer: a case study of women in Shiraz-Iran. Int J Health Policy Manage. 2014;2:187.","journal-title":"Int J Health Policy Manage"},{"key":"12003_CR76","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/M20-8076","volume":"175","author":"JT Schousboe","year":"2022","unstructured":"Schousboe JT, Sprague BL, Abraham L, et al. Cost-effectiveness of screening mammography beyond age 75 years: a cost-effectiveness analysis. Ann Intern Med. 2022;175:11\u20139.","journal-title":"Ann Intern Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12003-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T16:05:16Z","timestamp":1709309116000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12003"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12003-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors confirm that the experimental protocol and the study were approved by the ethics committee of Iran University of Medical Sciences. The authors confirm that all methods were performed following the relevant guidelines and regulations to this effect (Declaration of Helsinki). The authors confirmed that informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"279"}}